On 22 May 2019 Amgen Inc. announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) to tender all their shares in Nuevolution to Amgen (the "Offer") for SEK 32.50 per share in cash (the "Offer Price"). Nuevolution's shares are listed on Nasdaq Stockholm, Small Cap. Amgen has today published the offer document relating to the Offer (the "Offer Document"), which was approved and registered by the Swedish Financial Supervisory Authority on 12 June 2019. The Offer Document and the acceptance form are available at www.amgen.com/amgen/announcement and www.sebgroup.com/prospectuses.
The Offer Document, a pre-printed acceptance form and a self-addressed envelope will be distributed to shareholders of Nuevolution whose shares were directly registered with Euroclear Sweden AB as of 12 June 2019.
The acceptance period of the Offer commences on 13 June 2019 and expires on 4 July 2019. Settlement is expected to commence on or around 15 July 2019, subject to the conditions for completion of the Offer having been fulfilled or Amgen otherwise deciding to complete the Offer.
Amgen reserves the right to extend the acceptance period and to postpone the date of settlement. Amgen will announce any extension of the acceptance period and/or postponement of the settlement by a press release in accordance with applicable laws and regulations.